Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. [Review]
Citation: Expert Review of Clinical Immunology. 16(8):771-785, 2020 08.PMID: 32772596Institution: MedStar Georgetown University Hospital ResidentsForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Arthritis/ci [Chemically Induced] | *Immune Checkpoint Inhibitors/ae [Adverse Effects] | Arthritis/di [Diagnosis] | Arthritis/ep [Epidemiology] | Arthritis/th [Therapy] | Autoimmune Diseases/co [Complications] | Humans | Immune Checkpoint Inhibitors/pd [Pharmacology]Year: 2020ISSN:- 1744-666X
- Mollaeian, Arash:
- https://orcid.org/0000-0002-1483-2241
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 32772596 | Available | 32772596 |
AREAS COVERED: In this review, the authors focus on ICI-IIA. Relevant articles were identified through PubMed searches, spanning 2010 to the present. The authors detail the current understanding of its pathogenesis, diagnostic evaluation, and management strategies.
EXPERT OPINION: ICI-IIA is a complex irAE that we are just beginning to understand mechanistically and pathologically. It often presents later in the disease course than other irAEs and, due to various reasons, is under-recognized. In some patients, ICI-IIA may become a chronic disease, which distinguishes it from most irAEs that resolve after ICI discontinuation. Multiple important questions still demand further research including which patients may develop ICI-IIA? What are possible diagnostic and prognostic markers? Do anti-arthritis therapies interfere with the anti-tumor response? and when should steroid-sparing agents be initiated? Close collaboration and shared decision-making between oncologists, rheumatologists, and the patient are essential when managing this particular irAE.
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have proved to be groundbreaking in the field of oncology. However, immune system overactivation from ICIs has introduced a novel medical entity known as immune-related adverse events (irAEs), that can affect any organ or tissue. ICI-induced inflammatory arthritis (ICI-IIA) is the most common musculoskeletal irAE and can lead to significant morbidity and limitation in anti-cancer therapy.
English